{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:36:20Z","timestamp":1793320580400,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The cost-effectiveness acceptability curve (CEAC) is a method for summarizing the uncertainty in estimates of cost-effectiveness. The CEAC, derived from the joint distribution of costs and effects, illustrates the (Bayesian) probability that the data are consistent with a true cost-effectiveness ratio falling below a specified ceiling ratio. The objective of the paper is to illustrate how to construct and interpret a CEAC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective cost-effectiveness analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) randomized controlled trial with 4060 patients followed for 3.5 years. The target population was patients with atrial fibrillation who were 65 years of age or had other risk factors for stroke or death similar to those enrolled in AFFIRM. The intervention involved the management of patients with atrial fibrillation with antiarrhythmic drugs (rhythm-control) compared with drugs that control heart rate (rate-control). Measurements of mean survival, mean costs and incremental cost-effectiveness were made. The uncertainty surrounding the estimates of cost-effectiveness was illustrated through a cost-effectiveness acceptability curve.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The base case point estimate for the difference in effects and costs between rate and rhythm-control is 0.08 years (95% CI: -0.1 years to 0.24 years) and -US$5,077 (95% CI: -$1,100 to -$11,006). The CEAC shows that the decision uncertainty surrounding the adoption of rate-control strategies is less than 1.7% regardless of the maximum acceptable ceiling ratio. Thus, there is very little uncertainty surrounding the decision to adopt rate-control compared to rhythm-control for patients with atrial fibrillation from a resource point of view.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The CEAC is straightforward to calculate, construct and interpret. The CEAC is useful to a decision maker faced with the choice of whether or not to adopt a technology because it provides a measure of the decision uncertainty surrounding the choice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6963-6-52","type":"journal-article","created":{"date-parts":[[2006,4,20]],"date-time":"2006-04-20T15:47:09Z","timestamp":1145548029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":231,"title":["Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation"],"prefix":"10.1186","volume":"6","author":[{"given":"Elisabeth","family":"Fenwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian R","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Nichol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,12,1]]},"reference":[{"key":"229_CR1","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1136\/bmj.326.7401.1247","volume":"326","author":"P Bower","year":"2003","unstructured":"Bower P, Byford S, Barber J, Beecham J, Simpson S, Friedli K, Corney R, King M, Harvey I: Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses. BMJ. 2003, 326: 1247-1250. 10.1136\/bmj.326.7401.1247.","journal-title":"BMJ"},{"issue":"6","key":"229_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1017\/S0033291703008183","volume":"33","author":"S Byford","year":"2003","unstructured":"Byford S, Knapp M, Greenshields J, Ukoumunne O, Jones V, Thompson S, Tyrer P, Schmidt U, Davidson K, Group P: Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach. Psychol Med. 2003, 33 (6): 977-986. 10.1017\/S0033291703008183.","journal-title":"Psychol Med"},{"key":"229_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/bmj.326.7388.522","volume":"326","author":"J Chilcott","year":"2003","unstructured":"Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper N, Abrams K, Claxton K, Miller D, Group CEoMSTS: Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in mulitple sclerosis. BMJ. 2003, 326: 522-524. 10.1136\/bmj.326.7388.522.","journal-title":"BMJ"},{"key":"229_CR4","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(00)03308-0","volume":"356","author":"B Delaney","year":"2000","unstructured":"Delaney B, Wilson S, Roalfe A, Roberts L, Redman V, Wearn A, Briggs A, Hobbs F: Cost effectiveness of initial endoscopy for dypepsia in patients over age 50 years: a randomised controlled trial in primary care. Lancet. 2000, 356: 1965-1969. 10.1016\/S0140-6736(00)03308-0.","journal-title":"Lancet"},{"issue":"2","key":"229_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1378\/chest.124.2.526","volume":"124","author":"M Drummond","year":"2003","unstructured":"Drummond M, Becker D, Hux M, Chancellor J, Duprat-Lomon I, Kubin R, Sagnier P: An economic evaluation of sequential i.v.\/po moxifloxacin therapy compared to i.v.\/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest. 2003, 124 (2): 526-535. 10.1378\/chest.124.2.526.","journal-title":"Chest"},{"issue":"7246","key":"229_CR6","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/bmj.320.7246.1373","volume":"320","author":"A Gray","year":"2000","unstructured":"Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ. 2000, 320 (7246): 1373-1378. 10.1136\/bmj.320.7246.1373.","journal-title":"BMJ"},{"issue":"13","key":"229_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMsa020969","volume":"347","author":"B Manns","year":"2002","unstructured":"Manns B, Lee H, Doig C, Johnson D, Donaldson C: An economic evaluation of activated protein C treatment for severe sepsis. New England Journal of Medicine. 2002, 347 (13): 993-1000. 10.1056\/NEJMsa020969.","journal-title":"New England Journal of Medicine"},{"key":"229_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/bmj.325.7373.1135","volume":"325","author":"Multicentre Aneurysm Screening Group","year":"2002","unstructured":"Multicentre Aneurysm Screening Group: Multicentre aneurysm screening study (MASS):cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from a randomised controlled trial. BMJ. 2002, 325: 1135-1138. 10.1136\/bmj.325.7373.1135.","journal-title":"BMJ"},{"issue":"21","key":"229_CR9","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMsa030448","volume":"348","author":"S Ramsey","year":"2003","unstructured":"Ramsey S, Berry K, Etzioni R, Kaplan R, Sullivan S, Wood D, Group NETTR: Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. New England Journal of Medicine. 2003, 348 (21): 2092-2102. 10.1056\/NEJMsa030448.","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"229_CR10","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1161\/hc3901.096720","volume":"104","author":"R Sheldon","year":"2001","unstructured":"Sheldon R, O'Brien B, Blackhouse G, Goeree R, Mitchell B, Klein G, Roberts R, Gent M, Connolly S: Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation. 2001, 104 (14): 1622-1626.","journal-title":"Circulation"},{"key":"229_CR11","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/bmj.317.7160.720","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group: Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ. 1998, 317: 720-726.","journal-title":"BMJ"},{"issue":"9","key":"229_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.7326\/0003-4819-141-9-200411020-00005","volume":"141","author":"D Marshall","year":"2004","unstructured":"Marshall D, Levy A, Vidaillet H, Fenwick E, Slee A, Blackhouse G, Greene H, Wyse G, Nichol G, O'Brien B, et al: Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Annals of Internal Medicine. 2004, 141 (9): 653-661.","journal-title":"Annals of Internal Medicine"},{"key":"229_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick E, Claxton K, Sculpher M: Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 2001, 10: 779-787. 10.1002\/hec.635.","journal-title":"Health Econ"},{"key":"229_CR14","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1056\/NEJMoa021328","volume":"347","author":"G Wyse","year":"2002","unstructured":"Wyse G, Waldo A, DiMarco J, Domanski M, Rosenberg Y, Schron E: A comparison of rate control and rhythm control in patients with atrial fibrillation. New England Journal of Medicine. 2002, 347: 1825-1833.","journal-title":"New England Journal of Medicine"},{"key":"229_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/0272989X9001000308","volume":"10","author":"W Black","year":"1990","unstructured":"Black W: The CE plane: A graphic representation of cost-effectiveness. Medical Decision Making. 1990, 10: 212-214.","journal-title":"Medical Decision Making"},{"issue":"2 Suppl","key":"229_CR16","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","volume":"18","author":"AA Stinnett","year":"1998","unstructured":"Stinnett AA, Mullahy J: Net Health Benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998, 18 (2 Suppl): S68-80.","journal-title":"Med Decis Making"},{"key":"229_CR17","volume-title":"Health Tech Assess","author":"AH Briggs","year":"1999","unstructured":"Briggs AH, Gray A: Handling uncertainty when performing economic evaluation of healthcare interventions. Health Tech Assess. 1999, 3."},{"key":"229_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W","volume":"6","author":"AH Briggs","year":"1997","unstructured":"Briggs AH, Wonderling DE, Mooney CZ: Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Economics. 1997, 6: 327-340. 10.1002\/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W.","journal-title":"Health Economics"},{"key":"229_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V","volume":"9","author":"M Lothgren","year":"2000","unstructured":"Lothgren M, Zethraeus N: Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics. 2000, 9: 623-630. 10.1002\/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V.","journal-title":"Health Economics"},{"issue":"4","key":"229_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T","volume":"5","author":"A Willan","year":"1996","unstructured":"Willan A, O'Brien B: Confidence intervals for cost-effectiveness analysis ratios: an application of Fieller's theorem. Health Economics. 1996, 5 (4): 297-305. 10.1002\/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T.","journal-title":"Health Economics"},{"issue":"1","key":"229_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/0272989X9901900102","volume":"19","author":"DF Heitjan","year":"1999","unstructured":"Heitjan DF, Moskowitz AJ, Whang W: Problems with interval estimates of the incremental cost-effectiveness ratio. Medical Decision Making. 1999, 19 (1): 9-15.","journal-title":"Medical Decision Making"},{"key":"229_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2165\/00019053-200017040-00004","volume":"17","author":"A O'Hagan","year":"2000","unstructured":"O'Hagan A, Stevens JW, Montmartin J: Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics. 2000, 17: 339-349. 10.2165\/00019053-200017040-00004.","journal-title":"Pharmacoeconomics"},{"key":"229_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.0.CO;2-O","volume":"7","author":"A Briggs","year":"1998","unstructured":"Briggs A, Fenn P: Confidence intervals or surfaces ? Uncertainty on the cost-effectiveness plane. Health Economics. 1998, 7: 723-740. 10.1002\/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.0.CO;2-O.","journal-title":"Health Economics"},{"key":"229_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/hec.4730030505","volume":"3","author":"B Van Hout","year":"1994","unstructured":"Van Hout B, Al M, Gordon G, Rutten F: Costs, effects and c\/e-ratios alongside a clinical trial. Health Economics. 1994, 3: 309-319.","journal-title":"Health Economics"},{"key":"229_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1191\/0962280202sm304ra","volume":"11","author":"B O'Brien","year":"2002","unstructured":"O'Brien B, Briggs A: Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods in Medical Research. 2002, 11: 455-468. 10.1191\/0962280202sm304ra.","journal-title":"Statistical Methods in Medical Research"},{"key":"229_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/hec.903","volume":"13","author":"E Fenwick","year":"2004","unstructured":"Fenwick E, O'Brien B, Briggs A: Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Economics. 2004, 13: 405-415. 10.1002\/hec.903.","journal-title":"Health Economics"},{"issue":"9","key":"229_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.7326\/0003-4819-141-9-200411020-00016","volume":"141","author":"TD Bahnson","year":"2004","unstructured":"Bahnson TD, Grant AO: To be or not to be in normal sinus rhythm: What do we really know?. Annals of Internal Medicine. 2004, 141 (9): 727-729.","journal-title":"Annals of Internal Medicine"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-6-52.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6963-6-52\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-6-52","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-6-52.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T10:53:34Z","timestamp":1630493614000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/1472-6963-6-52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1186\/1472-6963-6-52","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]},"assertion":[{"value":"3 October 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"52"}}